



# ESMO Preceptorship on Gastroesophageal Cancer

## PROGRAMME

**ESMO  
PRECEPTORSHIP**

**LIMA PERU  
9-10 APRIL 2025**

**Co-Chairs**

Paola Montenegro, Peru  
Elizabeth Smyth, United Kingdom

# ESMO PRECEPTORSHIP PROGRAMME GASTROESOPHAGEAL CANCER

Multidisciplinary management, standards of care  
and future perspectives

Lima, Peru  
9-10 April 2025

---

## CO-CHAIRS

Paola Montenegro, Peru  
Elizabeth Smyth, United Kingdom

## SPEAKERS

Andrés Cervantes, Spain  
Tania Fleitas, Spain  
Marcelo Garrido, Chile  
Florian Lordick, Germany  
Guillermo Mendez, Argentina  
Alejandro Nieponice, Argentina  
Juan Manuel O'Connor, Argentina  
Cristian Pacheco, Peru  
Erika Ruiz-García, Mexico

---

## LEARNING OBJECTIVES

- To understand the best clinical practices in the multidisciplinary management of gastroesophageal cancer, both in the neoadjuvant and metastatic settings
- To comprehend the importance of pathology and histo-prognostic factors in the treatment of gastroesophageal cancers
- To learn how to manage patients after disease progression, addressing side effects of treatments and special situations
- To gain insights into the evolving field of biomarker-targeted therapy and immunotherapy for gastroesophageal cancer

---

## ACCREDITATION

The programme of this event has been accredited with **8 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is organised in collaboration with



---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4, 6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org) | [www.esmo.org](http://www.esmo.org)



## Wednesday, 9 April 2025

<b>14:30-14:45</b> <b>15'</b>	<b>Welcome and introduction</b>	<b>Paola Montenegro, PE</b> <b>Elizabeth Smyth, UK</b>
<b>14:45-15:50</b> <b>65'</b>	<b>SESSION 1</b> <b>Genetics &amp; epidemiology</b>	<b>Chairs:</b> <b>Florian Lordick, DE</b> <b>Juan Manuel O'Connor, AR</b>
15'	Epidemiology of gastroesophageal cancer in Latin America	Cristian Pacheco, PE
20'	Biology and biomarkers in gastroesophageal cancer	Tania Fleitas, ES
15'	Microbiota influence in gastroesophageal cancer	Erika Ruiz-García, MX
15'	Q&A	All
<b>15:50-16:20</b>	<b>Coffee break</b>	
<b>16:20-18:05</b> <b>105'</b>	<b>SESSION 2</b> <b>Operable gastroesophageal cancer</b>	<b>Chairs:</b> <b>Andrés Cervantes, ES</b> <b>Paola Montenegro, PE</b>
20'	Gastroesophageal junction cancer chemo vs. chemo radiotherapy	Juan Manuel O'Connor, AR
20'	Should immunotherapy be used in operable gastroesophageal adenocarcinoma?	Elizabeth Smyth, UK
20'	Surgery for gastric and gastroesophageal junction cancer: Which surgery and when?	Alejandro Nieponice, AR
15'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
<b>20:00</b>	<b>Networking dinner</b>	

## Thursday, 10 April 2025

<b>10:00-11:20</b> <b>80'</b>	<b>SESSION 3</b> <b>Treatment of advanced disease</b>	<b>Chairs:</b> <b>Tania Fleitas, ES</b> <b>Erika Ruiz-García, MX</b>
20'	Chemotherapy for advanced gastric cancer	Florian Lordick, DE
20'	Second line and third line treatments	Paola Montenegro, PE
10'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
<b>11:20-11:50</b>	<b>Coffee break</b>	

<b>11:50-13:05</b> 80'	<b>SESSION 4</b> <b>Biomarker targeted therapy and immunotherapy</b>	<b>Chairs:</b> <b>Alejandro Nieponice, AR</b> <b>Elizabeth Smyth, UK</b>
20'	Sequencing HER2 directed therapy	Andrés Cervantes, ES
20'	Immunotherapy new challenges	Marcelo Garrido, CL
20'	Emerging therapies; claudin 18.2, FGFR2, etc.	Tania Fleitas, ES
15'	Q&A	All
<b>13:05-14:05</b>	<b>Lunch</b>	
<b>14:05-15:35</b> 90'	<b>SESSION 5</b> <b>Oligometastatic gastroesophageal cancer</b>	<b>Chairs:</b> <b>Andrés Cervantes, ES</b> <b>Erika Ruiz-García, MX</b>
40'	DEBATE: Patients with oligometastatic gastroesophageal cancer should be surgical candidates - YES - NO	Alejandro Nieponice, AR Guillermo Mendez, AR
20'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
<b>15:35-16:05</b>	<b>Coffee break</b>	
<b>16:05-17:05</b> 60'	<b>SESSION 6</b> <b>Challenging clinical situations: Case presentations</b>	<b>Chair:</b> <b>Marcelo Garrido, CL</b>
5'	Case of squamous cell cancer: To operate or not to operate?	Guillermo Mendez, AR
15'	Q&A	All
5'	Case of gastric cancer signet ring cells that requires neoadjuvant therapy	Paola Montenegro, PE
15'	Q&A	All
5'	Case of gastric cancer with neoadjuvant therapy operated without response	Florian Lordick, DE
15'	Q&A	All
<b>17:05-17:15</b> 10'	<b>Closing remarks</b>	<b>Paola Montenegro, PE</b> <b>Elizabeth Smyth, UK</b>

**Note:** Each 15-minute slot for clinical case discussion includes 5' case presentation and 10' Q&A / panel discussion